<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Pediatr</journal-id><journal-id journal-id-type="iso-abbrev">J Pediatr</journal-id><journal-id journal-id-type="pmc-domain-id">2530</journal-id><journal-id journal-id-type="pmc-domain">hhspa</journal-id><journal-title-group><journal-title>The Journal of pediatrics</journal-title></journal-title-group><issn pub-type="ppub">0022-3476</issn><issn pub-type="epub">1097-6833</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>HHS Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10448738</article-id><article-id pub-id-type="pmcid-ver">PMC10448738.2530</article-id><article-id pub-id-type="pmcaid">10448738</article-id><article-id pub-id-type="pmcaiid">10448738</article-id><article-id pub-id-type="manuscript-id">NIHMS1923302</article-id><article-id pub-id-type="pmid">37023948</article-id><article-id pub-id-type="doi">10.1016/j.jpeds.2023.113409</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1923302</article-id><article-id pub-id-type="manuscript-id-alternative">HHSPA1923302</article-id><article-version article-version-type="pmc-version">2530</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Cost-effectiveness of Strategies to Identify Children with Perinatally Acquired Hepatitis C Infection</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hall</surname><given-names initials="EW">Eric W.</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Panagiotakopoulos</surname><given-names initials="L">Lakshmi</given-names></name><degrees>MD</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wester</surname><given-names initials="C">Carolyn</given-names></name><degrees>MD</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nelson</surname><given-names initials="N">Noele</given-names></name><degrees>MD</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sandul</surname><given-names initials="AL">Amy L</given-names></name><degrees>DHSc</degrees><xref rid="A2" ref-type="aff">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Oregon Health &amp; Science University, Portland, Oregon</aff><aff id="A2"><label>2</label>Division of Viral Hepatitis, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia</aff><author-notes><corresp id="CR1"><bold>Corresponding Author:</bold> Eric Hall, OHSU-PSU School of Public Health, 1810 SW 5th Avenue, Suite 510, Portland, OR 97201, <email>halleri@ohsu.edu</email> &#8739; (P) 503-494-4966</corresp><fn fn-type="COI-statement" id="FN2"><p id="P25">Conflict of Interest Disclosures:</p><p id="P26">Author EWH reports receiving consulting fees from Merck &amp; Co. for work unrelated to this research. All other authors have no conflicts of interest to report. LP, NN, CW, and ALS report salaries as employees at the US Centers for Disease Control and Prevention.</p></fn></author-notes><pub-date pub-type="ppub"><month>7</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>04</day><month>4</month><year>2023</year></pub-date><volume>258</volume><issue-id pub-id-type="pmc-issue-id">443905</issue-id><fpage>113409</fpage><lpage>113409</lpage><pub-history><event event-type="nihms-submitted"><date><day>16</day><month>08</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>07</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>07</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-19 21:25:15.690"><day>19</day><month>05</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1923302.pdf"/><abstract id="ABS1"><sec id="S1"><title>Objectives:</title><p id="P1">We aimed to determine the optimal testing strategy to identify children with perinatally acquired hepatitis C virus (HCV) infection.</p></sec><sec id="S2"><title>Study Design:</title><p id="P2">We used a decision-tree framework with a Markov disease progression model to conduct an economic analysis of four strategies, based on combinations of type and timing of test: Anti-HCV with reflex to HCV RNA at 18 months among children known to be perinatally exposed (ie, baseline comparison strategy); HCV RNA testing at 2&#8211;6 months among infants known to be perinatally exposed (Test Strategy 1); universal anti-HCV with reflex to HCV RNA at 18 months among all children (Test Strategy 2); universal HCV RNA testing at 2&#8211;6 months among all infants (Test Strategy 3). We estimated total cost, quality-adjusted life years (QALYs), and disease sequalae for each strategy.</p></sec><sec id="S3"><title>Results:</title><p id="P3">Each of the three alternative testing strategies resulted in an increased number of children tested and improved health outcomes. HCV RNA testing at 2&#8211;6 months (Test Strategy 1) was cost-saving and resulted in a population-level difference in cost of $469,671. The two universal testing strategies resulted in an increase in QALYs and an increase in total costs.</p></sec><sec id="S4"><title>Conclusions:</title><p id="P4">Testing of perinatally exposed infants at age 2&#8211;6 months with a single HCV RNA test will reduce costs and improve health outcomes, preventing morbidity and mortality associated with complications from perinatal HCV infections.</p></sec></abstract><kwd-group><kwd>hepatitis C virus</kwd><kwd>diagnosis</kwd><kwd>economic evaluation</kwd><kwd>maternal antibodies</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>